ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Arbutus Biopharma Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$4.23+0.01 (+0.24%)

Close on Oct 19, 2026

Community

Notes and questions about Arbutus Biopharma from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Arbutus Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Nov 4, 2010
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABUS.

Revenue growth1078.8% · median 53.2%

Operating margin82.0% · median -14.0%

Net margin84.2% · median -23.6%

Advertisement
300 × 250